The Effect of Dapagliflozin in Improving Ejection Fraction

This project is about to evaluatethe effect of Dapagliflozin in improving ejection fraction and observe the effect of dapagliflozin in hospitalization of cardiovascular diseases like Heart failure.It was a Prospective observational studyconducted from October 2023 to April 2024 at Lalitha Super Specialty Hospital Guntur. A sample size of 60 patients were taken, all the necessary and relevant data was collected from the patient case notes, treatment charts and laboratory reports. Heart failure is a serious, progressive condition that occurs when heart muscle can’t able to pump enough blood to meet body needs for blood and oxygen.Between 1990 and 2000, the number of deaths in India from cardiovascular illnesses increased from 2.26 million to 4.7 million annually. The amount of blood that the left ventricle pumps out with each contraction is measured and represented as the ejection fraction. Guidelines strongly advise using SGLT2 inhibitors to treat individuals with HF who have a decreased ejection fraction. In our study among 60 patients during and after therapy the considerable changes have seen in cardiac function through ECHO, ECG and symptomatic relief. The positive aspects towards the EF and symptomatic relief have been observed. The patients who are admitted with heart failure have shown positive response towards SGLT2 inhibitors.